CLINICAL TRIALS PROFILE FOR ONIVYDE
✉ Email this page to a colleague
All Clinical Trials for Onivyde
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02231723 ↗ | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | Completed | Boston Biomedical, Inc | Phase 1 | 2014-08-01 | This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin. |
NCT02231723 ↗ | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | Completed | Sumitomo Dainippon Pharma Oncology, Inc | Phase 1 | 2014-08-01 | This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin. |
NCT02631733 ↗ | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2016-07-15 | This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Onivyde
Condition Name
Clinical Trial Locations for Onivyde
Trials by Country
Clinical Trial Progress for Onivyde
Clinical Trial Phase
Clinical Trial Sponsors for Onivyde
Sponsor Name